Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, discusses the need for more patient assistance foundations to help patients pay for treatment.
Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, discusses the need for more patient assistance foundations to help patients pay for treatment.
Transcript
What is the overall impact that patient assistance foundations, like PAN, have on helping patients access treatments?
Well we serve anywhere between 150,000 to 250,000 patients a year depending on how much funding we have available. In the past couple of years, we’ve served about 150,000 patients a year and we’re the largest of the major charitable foundations so we’re serving about 40% to 50% of the patients who get charitable assistance. My guess is, there are probably 1 million or so patients a year getting charitable support from the 7 to 9 largest foundations.
The problem is that we can’t serve everybody who comes to us for a grant. Now we do refer them to other charities. But my guess is that there are 2 or 3 times the number of people who need help who can’t actually get it.
How do you envision the role of PAN will change and expand as more novel therapies that are potentially curative, but expensive, come to market?
The worry we have is some of these very innovative new therapies, like CAR T therapies, other gene therapies, are going to be so expensive that health plans may struggle to find ways to pay for them and patient out-of-pocket costs could be essentially unaffordable for patients. So, we think they’re gonna be probably new ways to finance these kinds of treatments that will spread the cost over a longer period than the traditional benefit does. We are not sure what those will be but we know that half a million dollar and million dollar products come to the market, there are going to have to be new ways to finance those.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More